Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Conor J. Kirby"'
Autor:
Alexandra Drakaki, Simon Chowdhury, Chia-Chi Lin, Daniel Keizman, Michiel S. van der Heijden, Daniel P. Petrylak, Jae-Lyun Lee, Kim N. Chi, Sergio Bracarda, Daniel Castellano, Georgios Gakis, Andrea Necchi, Lajos Géczi, Ulka N. Vaishampayan, Annamaria Zimmermann, Thomas Powles, Conor J. Kirby, Katherine M Bell-McGuinn, Aude Flechon
Publikováno v:
Bladder Cancer, 6(1), 43-52. IOS Press
BACKGROUND: The phase 3 RANGE trial found ramucirumab/docetaxel improved progression-free survival (PFS) versus placebo/docetaxel (median 4.1 vs 2.8 months; hazard ratio [HR] = 0.757, p = 0.0118) for treatment of platinum-refractory metastatic urothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9131c145fbae3b8eeeb9001f6d11400d
http://www.scopus.com/inward/record.url?scp=85083061281&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85083061281&partnerID=8YFLogxK
Autor:
Alexandra Drakaki, Daniel P. Petrylak, Andrea Necchi, Chia-Chi Lin, Daniel Keizman, Annamaria Zimmermann, Simon Chowdhury, Kim N. Chi, Daniel Castellano, Lajos Géczi, Georgios Gakis, Astra M. Liepa, Jae-Lyun Lee, Katherine M Bell-McGuinn, Michiel S. van der Heijden, Thomas Powles, Aude Flechon, Conor J Kirby, Ulka N. Vaishampayan, Sergio Bracarda
Publikováno v:
Journal of Clinical Oncology. 36:434-434
434 Background: Immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 have shown objective response rates (ORR) of 15-21% in PD-L1 unselected patients (pts) with platinum-refractory mUC. Overall results of RANGE, a randomized, double-blinded phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a2e97d9770697fa6c12228bb0ddd00b
https://doi.org/10.1200/jco.2018.36.6_suppl.434
https://doi.org/10.1200/jco.2018.36.6_suppl.434